



Comparison of Sutureless Versus Suture Partial Nephrectomy for Clinical T1 Renal Cell Carcinoma: A Meta-Analysis of Retrospective Studies

Wenjun Zhang^{1†}, Bangwei Che^{1†}, Shenghan Xu^{1†}, Yi Mu¹, Jun He¹ and Kaifa Tang^{1,2*}

¹ Department of Urology, Affiliated Hospital of Guizhou Medical University, Guiyang, China, ² Institute of Medical Science of Guizhou Medical University, Guiyang, China

OPEN ACCESS

Edited by:

Antonio Augusto Ornellas, National Cancer Institute (INCA), Brazil

Reviewed by:

Ari Adamy, Santa Casa Hospital, Brazil Paulo Ornellas, Marcílio Dias Naval Hospital, Brazil

> *Correspondence: Kaifa Tang

tangkaifa@gmc.edu.cn [†]These authors have contributed

equally to this work

Specialty section:

This article was submitted to Genitourinary Oncology, a section of the journal Frontiers in Oncology

Received: 23 May 2021 Accepted: 13 August 2021 Published: 02 September 2021

Citation:

Zhang W, Che B, Xu S, Mu Y, He J and Tang K (2021) Comparison of Sutureless Versus Suture Partial Nephrectomy for Clinical T1 Renal Cell Carcinoma: A Meta-Analysis of Retrospective Studies. Front. Oncol. 11:713645. doi: 10.3389/fonc.2021.713645 **Background:** Partial nephrectomy (PN) is the recommended treatment for T1 renal cell carcinoma (RCC). Compared with suture PN, sutureless PN reduces the difficulty and time of operation, but the safety and feasibility have been controversial. This meta-analysis was conducted to compare the function and perioperative outcomes of suture and sutureless PN for T1 RCC.

Methods: Systematic literature review was performed up to April 2021 using multiple databases to identify eligible comparative studies. According to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) criteria, identification and selection of the studies were conducted. Meta-analysis was performed for studies comparing suture to sutureless PN for both T1a and T1b RCC. In addition, subgroup analysis was performed on operation time, warm ischemia time, estimated blood loss, and postoperative complications. Sensitivity analysis was used in analysis with high heterogeneity (operation time and estimated blood loss).

Results: Eight retrospective studies were included with a total of 1,156 patients; of the 1,156 patients, 499 received sutureless PN and 707 received suture PN. The results showed that sutureless PN had shorter operative time ($l^2 = 0\%$, P < 0.001), warm ischemia time ($l^2 = 97.5\%$, P < 0.001), and lower clamping rate ($l^2 = 85.8\%$, P = 0.003), but estimated blood loss ($l^2 = 76.6\%$, P = 0.064) had no difference. In the comparison of perioperative outcomes, there was no significant difference in postoperative complications ($l^2 = 0\%$, P = 0.999), positive surgical margins ($l^2 = 0\%$, P = 0.356), postoperative estimated glomerular filtration rat (eGFR) ($l^2 = 0\%$, P = 0.656), and tumor recurrence ($l^2 = 0\%$, P = 0.531).

Conclusions: In T1a RCC with low RENAL score, sutureless PN is a feasible choice, whereas it should not be overestimated in T1b RCC.

Keywords: partial nephrectomy, renal cell carcinoma, meta-analysis, suture, sutureless

1

INTRODUCTION

Partial nephrectomy (PN), in the surgical treatment of T1 renal cell carcinoma (RCC), is recommended according to the guidelines of the American Urology Association (AUA) and European Association of Urology (EAU) (1, 2). PN can provide better protection of renal function (3, 4), reduce the risk of severe cardiovascular events, and improve overall survival (5). However, the learning curve of PN is steep (6). In order to avoid the warm ischemic injury, the ischemic time usually limit to 25 min (7). Complete tumor resection, hemostasis, and suture in a limited time is a great challenge.

In recent years, some urologists have been focused on sutureless PN and tried to prove its safety and feasibility (2, 8– 17). Without suture, the difficulty of operation is reduced, and the operation time is saved. However, the lack of reliable renal parenchyma suture may increase the potential risk of postoperative complications, which is controversial.

The superiority of PN in the surgical treatment of T1 RCC has been fully confirmed; by contrast, there is no meta-analysis comparing suture and sutureless PN. To fill this gap, we designed the present meta-analysis to compare the function and perioperative outcomes of the two techniques in PN for T1 RCC.

METHOD

Search Strategy

A literature search was performed in multiple databases (PubMed, Embase, and Web of Science) up to April 2021 to identify studies comparing suture to sutureless PN for T1 RCC. The diagnosis (kidney neoplasms, kidney cancer, renal carcinoma, renal tumor) and intervention (partial nephrectomy, nephron preservation and suture, surureless, and suture free) were used, respectively. We carried on the reference list search and citation literature retrieval for the full-text literature that met the research selection criteria.

Inclusion Criteria, Study Eligibility, and Data Extraction

The Preferred Reporting Items for Systematic Reviews and Metaanalysis (PRISMA) criteria were used for article selection (Figure 1), which was performed by two investigators (WZ and BC). The following study types were included: original studies comparing suture and sutureless PN were included regardless of the technique. All titles were screened for manuscripts written in the English language and only on adult patients. All studies were determined to include perioperative or functional outcomes. The titles of the articles were first reviewed to determine whether they might potentially fit the inclusion criteria. After assessing the abstract, a more comprehensive assessment was conducted by viewing the full text to determine whether the study should be included. Studies without primary data (i.e., case report reviews, commentaries, letters, and conference abstract) were excluded, but the reference lists were examined to identify that additional studies of interest had been

included. References from the included studies were manually reviewed to identify additional studies of interest. Disagreement on whether or not an article should be included was resolved using a third reviewer (KT).

Assessment of Study Quality

The quality of each study was determined using the Newcastle– Ottawa Scale (NOS) for nonrandomized controlled trials. The maximum score of the scale is 9. A total score of 5 or lower is considered low quality, 6–7 is considered intermediate quality, and 8–9 is considered high quality. Two researchers evaluated each study independently.

Data Analysis

Data were extracted using a predefined data extraction form. Baseline demographics (age, T stage, RENAL Score, and baseline renal function), perioperative data (operative time, warm ischemia time, estimated blood loss, postoperative complications, surgical margins, and clamping rate), functional parameters [postoperative estimated glomerular filtration rat (eGFR)] and oncological outcome parameters (tumor recurrence) were extracted from the studies whenever available. For continuous outcomes, weighted mean difference (WMD) was used to measure differences; the risk ratio (RR) with 95% confidence interval (CI) was calculated for binary variables. For studies reporting medians and ranges [or interquartile ranges (IQR)], validated mathematical models were used to convert the median (range or IQR) to the mean [standard deviation (SD)] (18, 19). Between-study statistical heterogeneity was assessed using I^2 and the Cochrane Q test. If there is no significant heterogeneity between the studies (P > 0.10, $I^2 < 50\%$), pooled estimates were calculated using a fixed-effects model; otherwise, using random effects model (P < 0.10, $I^2 > 50\%$). The significance level was set to α = 0.05, and 95%CI was taken. Begg's and Egger's tests were used to detect publication bias. Sensitivity analysis was used in high heterogeneity analysis to test the stability of the conclusion. This research used statistical software Stata12.0 to merge data.

RESULTS

This analysis included eight retrospective case-control studies with a total of 1,156 patients. All the included studies were compared the sutureless and suture techniques in laparoscopic PN for T1 tumors. Two of the studies used propensity score to match the preoperative baseline characteristics (**Table 1**). Subgroup analysis was performed between uncomplex (studies only included T1a RCC and RENAL score < 6) and complex subgroups (studies included T1b RCC and RENAL score \geq 6), including operation time, warm ischemia time, estimated blood loss, and postoperative complications. Among the selected article, postoperative follow-up observation was carried out in six articles; only two articles reported recurrence. In addition, four articles compared postoperative eGFR. Due to different renal function evaluation criteria, we only selected two articles with the same criteria for meta-analysis. We analyzed the



Study	Study period	Study design	Study origin	T stage		Sutureless/sutu	re	Surgical technique	SQ
					Cases (n)	RENAL score	FU (months)		
Feng Zhang (11)	2015–2018	RTP, MI, PSM	China	T1a-1b	116/116	6 ^a /6 ^a	6	Lap, Elec, Bio, RAC	7
Ching-Chia Li (14)	2015-2018	RTP, MI	China	T1a	33/19	5.7 ^a /5.9 ^a	29.3 ^a /27.5 ^a	sLap, Elec, Bio, RAC	7
Dachun Jin (10)	2014-2019	RTP, MI, PSM	China	T1a	65/189	5.3 ^a /5.9 ^a	22 ^a	Lap, Elec, Bio, RAC	7
Daniele Tiscione (16)	2008-2009	RTP, MI	Italy	T1a	19/21	9.6 ^a /9.4 ^a	79.6	Lap, Bio, RAC	7
Jianfei Ye (10)	2012-2016	RTP, MI	China	T1a	78/126	4.8 ^a /6.5 ^a	47.2 ^a /49.3 ^a	Lap, Elec, Bio, RAC	6
Andrea Minervini (13)	2007-2010	RTP, MI	Italy	T1a	32/68	NA	NA	Lap, Elec, RAC	6
G. Hidas (17)	1993–2005	RTP, MI	Israel	T1a-1b	31/143	NA	NA	Lap, Elec, Bio, RAC	6
William. J 2005 (12)	1998–2004	RTP, MI	USA	T1a	75/25	NA	20.3 ^a	Lap, Elec, Bio, RAC	7

Bio, biohemostatic material; Elec, electrocoagulation; FU, follow-up; Lap, laparoscopic; PSM, propensity score matching; RTP, retrospective; RAC, renal artery clamping; SC, single center; SQ, study quality according to the Newcastle–Ottawa scale; NA, not applicable. ^aMedian.

baseline characteristics according to tumor size, age, and preoperative renal function and evaluated selection bias to obtain more convincing conclusions (**Table 2**).

In perioperative outcomes, the operation time was different (I 2 = 0; WMD, -24.836; 95%CI, -28.727, -20.945; P < 0.001),

and subgroup analysis showed that sutureless PN has shorter operation time than suture PN in uncomplex subgroup ($I^2 = 0$; WMD, -20.053; 95%CI, -35.599 to -4.507; P = 0.011) and complex subgroup ($I^2 = 0$; WMD, -25.155; 95%CI, -29.174 to -21.137; P < 0.001). Difference also existed in the warm ischemia

TABLE 2	Summar	y of baseline characteristics and outcomes of different analyses	
---------	--------	--	--

Outcomes	Included studies	lies Baseline, WMD or RR		95% CI)		
		Age	Tumor size	Preoperative eGFR, mL/min/m		
operative time, min	7	0.559 (-0.974, 2.091)	-0.190 (-0.543, 0.162)	NA		
warm ischemia time, min	8	0.747 (-0.906, 2.400)	-0.223 (-0.525, 0.080)	NA		
Ischemia rate, %	3	1.830 (-3.105, 6.765)	NA	NA		
Estimated blood loss, ml	8	0.559 (-0.974, 2.091)	-0.223 (-0.525, 0.080)	NA		
Postoperative complications	7	0.584 (-0.963, 2.131)	-0.223 (-0.525, 0.080)	NA		
Preoperative eGFR ml/min/m ²	2	3.638 (-3.018, 10.294)	0.200 (-0.193, 0.593)	-2.651 (-8.236, 2.933)		
Positive surgical margin	4	1.529 (-0.575, 3.633)	-0.161 (-0.320, -0.002)	NA		
Tumor recurrence	2	1.562 (-1.850, 4.975)	-0.200 (-0.375, -0.025)	NA		

WIMD, weighted mean difference; CI, confidence interval; eGFR, estimated glomerular filtration rat; NA, not applicable; RP, risk ratio.

time (I² = 97.5; WMD, -8.335; 95%CI, -12.254 to -4.416; P < 0.001). In subgroup analysis, the ischemia time of sutureless PN was shorter than that of suture PN in the uncomplex subgroup (I² = 97.9%; WMD, -6.575; 95%CI, -7.852 to -5.298; P < 0.001) and complex subgroup (I² = 0; WMD, -9.306; 95%CI, -14.433 to -4.179; P < 0.001) (**Figure 2**). In addition, the rate of warm ischemia in the sutureless PN was lower than that in the suture

PN (I² = 85.8%; RR, 0.447; 95%CI, 0.264, 0.756; P = 0.003). There was no difference in estimated blood loss (I² = 76.6%; WMD, -27.529; 95%CI, -56.645 to 1.588; P = 0.064); further subgroup analysis found sutureless PN had less blood loss in the complex subgroup (I² = 0%; WMD, -105.175; 95%CI, -156.824 to -53.527; P < 0.001), while blood loss in the uncomplex subgroup had no difference (I² = 77.8%; WMD, -10.198;



95%CI, -56.645 to 1.588; P = 0.064) (Figure 3). There was no significant difference in postoperative complications (I² = 0; RR, 0.915; 95%CI, 0.578–1.449; P = 0.999), positive surgical margin (I² = 0; RR, 0.604; 95%CI, 0.207–1.761; P = 0.356), postoperative renal function (I² = 0; WMD, -1.491; 95%CI, -8.049 to 5.066; P = 0.656), and tumor recurrence (I² = 0; RR, 0.55; 95%CI, -0.085 to 3.573; P = 0.531) (Figures 4 and 5).

Sensitivity analysis was used in analysis with high heterogeneity (operation time and estimated blood loss). After excluding the study of Jianfei Ye et al. (13), the heterogeneity of warm ischemia time decreased (I² from 97.5% to 25.3%), but the results were consistent with previous studies. In addition, in comparing operation time, after excluding the study of Dachun Jin et al. (10), the results were also consistent with the previous studies.

Begg's and Egger's tests found no significant publication bias (Table 3).

DISCUSSION

At present, PN is the recommended method for surgical treatment of T1 tumors (1). A successful PN operation included surgical margin, slight decrease in renal function, and no serious postoperative complications (20). Maximum preservation of renal function is the original intention of PN (21). Saving the time of ischemia could reduce renal damage (22). In this study, sutureless PN had advantages in shortening the ischemia time and reducing operative blood loss. In addition, the rate of complete renal artery clamping was lower in the sutureless PN, which might have a potential advantage in the protection of postoperative renal function (23, 24).

Without reconstruction, sutureless PN could reduce the operation difficulty, which could reduce operation time. Although the lack of reconstruction might bring potential risks, in comparison of operative blood loss and postoperative complications, the application of



5

	sutu	reless	suti	ire			Risk l	Ratio			Risk Rat	io		
Study or Subgroup	Case	Events	Case	Events	Weight,	RR	M-H, Fixe	ed, 95%C	Ι	M-	H, Fixed, 9	95%CI		
T1a or REANL<6														
Ching-Chia Li 2020	33	2	19	0	1.75%	2.941	[0.149, 5	58.237]						
Dachun Jin 2020	65	6	189	21	29.95%	0.831	[0.351,	1.968]				•		
Jianfei Ye 2018	78	7	126	9	19.18%	1.256	[0.488,	3.237]			-	-		
Andrea Minervini 2014	32	0	68	7	13.52%	0.139	[0.008,	2.368]			•• !	-		
William.J (2006)	75	18	25	4	16.72%	1.5	[0.561,	4.014]						
Subtotal	283		427		81.14%	1	[0.605,	1.652]			Ţ			
Ieterogeneity: Chi ² = 3	3.41, df	= 4, (P =	0.491);	$I^2 = 0\%$							\Rightarrow	•		
est for overall effect:											1			
T1b or RENAL≥6											i			
Daniele Tiscione 2019	19	2	21	6	15.89%	0.368	[0.084,	1.611]		_	•			
G.Hidas 2006	31	1	143	3	2.98%	1.538	[0.165,]	14.294]			_			
Subtotal	50		164		18.86%	0.553	[0.171,	1.785]			$\langle \rangle$	•		
Heterogeneity: $Chi^2 = 1$ Test for overall effect:	Z= 0.99		22)		100.000/	0.015	10 579	1 4 4 0 1						
	222													
Total	333	26	591		100.00%	0.915	[0.578,	1.449]			I			
Cotal events		36		50	100.00%	0.915	[0.578,	1.449]						
Cotal events Heterogeneity: Chi ² = :	5.4, df=	= 6, (P =	0.494) I	50	100.00%	0.915	[0.578,	1.449]	-0.001	-0.1	 	10	100	
Cotal events	5.4, df=	= 6, (P =	0.494) I	50	100.00%	0.915	[0.578,	1.449]	-0.001			10 wors Suture	100	
Cotal events Heterogeneity: Chi ² = :	5.4, df = Z= 0.38	= 6, (P = 0.7)	0.494) I '06)	$50^2 = 0\%$		0.915	[0.578,	1.449]	-0.001				100	
Total events Heterogeneity: Chi ² = : Test for overall effect:	5.4, df = Z= 0.38	= 6, (P = 0.7)	0.494) I '06)	$50^2 = 0\%$		0.915	[0.578,	1.449]	-0.001				100	
Total events Heterogeneity: Chi ² = : Tots for overall effect: RR = risk ritio, SD = s	5.4, df ⁼ Z= 0.38 tandard	= 6, (P = 0.7) , $(P = 0.7)$ deviation	0.494) I '06)	$50^2 = 0\%$		0.915	[0.578,	1.449]	-0.001				100	
Total events Heterogeneity: Chi ² = : Test for overall effect:	5.4, df ⁼ Z= 0.38 tandard margi	= 6, (P = 0.7) , $(P = 0.7)$ deviation	0.494) I '06)	50 $^2 = 0\%$		0.915	[0.578,				tureless Fa	wors Suture	100	
Total events Heterogeneity: Chi ² = : Test for overall effect: RR = risk ritio, SD = s Positive surgical	5.4, df ⁼ Z= 0.38 tandard margi	= 6, (P = 0.7) , $(P = 0.7)$ deviation n n nutureless	0.494) I (06) ; CI = co	$50^2 = 0\%$	interval.			Ris	sk Ratio	Favors Su	tureless Fa	wors Suture sk Ratio		
Total events Heterogeneity: Chi ² = 2 Cest for overall effect: RR = risk ritio, SD = s Positive surgical Study or Subgroup	5.4, df ⁼ Z= 0.38 tandard margi st Cas	= 6, $(P = 0.7$, $(P = 0.7$ deviation) n n n tureless e Event	0.494) I (06) ; CI = co	$50^{2} = 0\%$ onfidence suture e Even	interval. Its We	ight	RR	Ris M-H, Fi	sk Ratio ixed, 95%CI	Favors Su	tureless Fa	wors Suture		
Total events Heterogeneity: Chi ² = 2 Cest for overall effect: RR = risk ritio, SD = s Positive surgical Study or Subgroup Feng Zhang 2021	5.4, df ⁼ Z= 0.38 tandard margi su Cas 110	= 6, (P = 0.7) $= 0.7$ $= 0.7$ $= 0.7$ $= 0.7$ $= 0.7$ $= 0.7$	$\begin{array}{c} 0.494) \text{ I}\\ 066)\\ \text{; CI = co}\\ \hline \\ \text{(s) Cas}\\ \hline \\ 110 \end{array}$	50 $^{2} = 0\%$ onfidence suture $e Even 5 3$	tts We 35.5	ight 7%	RR 0.667	Ris M-H, F [0.11	sk Ratio ixed, 95%CI [3, 3.916]	Favors Su	tureless Fa	wors Suture sk Ratio		
Total events Heterogeneity: Chi ² = 2 Cest for overall effect: RR = risk ritio, SD = s Positive surgical Study or Subgroup	5.4, df ⁼ Z= 0.38 tandard margi su Cas 110	P = 6, (P = 0.7) $(P = 0.7)$	0.494) I (06) ; CI = co :s Cas	50 $^{2} = 0\%$ onfidence $\frac{\text{suture}}{6 - 3}$ 0	ts We 35.3 7.4	ight 57% 7%	RR	Ris M-H, F [0.11 [0.14]	sk Ratio ixed, 95%CI	Favors Su	tureless Fa	wors Suture sk Ratio		
Total events Ieterogeneity: Chi ² = 2 Positive surgical Study or Subgroup Feng Zhang 2021 Ching-Chia Li 2020	5.4, df = Z= 0.38 tandard margi st Cas 110 33	\mathbf{n}	(0.494) I (06) (CI = co (5) Cas (10) (19) (19)	50 $^{2} = 0\%$ suture $e Even$ $5 3$ 0 3	tts We 35.5	ight 7% 7%	<u>RR</u> 0.667 2.941	Ris M-H, Fi [0.11 [0.149 [0.02	sk Ratio ixed, 95%CI 3, 3.916] 9, 58.237]	Favors Su	tureless Fa	wors Suture sk Ratio		
Total events Teterogeneity: Chi ² = 2 Positive surgical Study or Subgroup Feng Zhang 2021 Ching-Chia Li 2020 Dachun Jin 2020	5.4, df = Z= 0.38 tandard margi SI Cas 110 33 65	\mathbf{n}	$\begin{array}{c} 0.494) I \\ 060 \\ CI = cc \\ s \\ Cas \\ 11c \\ 19 \\ 185 \end{array}$	50 $^{2} = 0\%$ onfidence suture $e Even 5 3 0 3 2$	ts We 35.5 7.4 21.4 35.5	ight 7% 7% 40% 57%	RR 0.667 2.941 0.411	Ris M-H, Fi [0.11 [0.14 [0.02 [0.01	sk Ratio ixed, 95%CI (3, 3.916) 9, 58.237] 22, 7.857]	Favors Su	tureless Fa	wors Suture sk Ratio		
Total events Teterogeneity: Chi ² = 2 Test for overall effect: RR = risk ritio, SD = s Positive surgical Study or Subgroup Feng Zhang 2021 Ching-Chia Li 2020 Dachun Jin 2020 William.J 2005	5.4, df = Z= 0.38 tandard margi Cas 110 33 65 75	\mathbf{n}	$\begin{array}{c} 0.494 \\ 1060 \\ 0.61 \\ 0$	50 $^{2} = 0\%$ onfidence suture $e Even 5 3 0 3 2$	ts We 35.5 7.4 21.4 35.5	ight 7% 7% 40% 57%	RR 0.667 2.941 0.411 0.167	Ris M-H, Fi [0.11 [0.14 [0.02 [0.01	sk Ratio ixed, 95%CI (3, 3.916) 9, 58.237] 22, 7.857] (6, 1.761]	Favors Su	tureless Fa	wors Suture sk Ratio		
Total events Teterogeneity: Chi ² = 2 Test for overall effect: RR = risk ritio, SD = s Positive surgical Study or Subgroup Feng Zhang 2021 Ching-Chia Li 2020 Dachun Jin 2020 William.J 2005	5.4, df = Z= 0.38 tandard margi Cas 110 33 65 75	\mathbf{n}	$\begin{array}{c} 0.494 \\ 1060 \\ 0.61 \\ 0$	50 $^{2} = 0\%$ onfidence suture $e Even 5 3 0 3 2$	ts We 35.5 7.4 21.4 35.5	ight 7% 7% 40% 57%	RR 0.667 2.941 0.411 0.167	Ris M-H, Fi [0.11 [0.14 [0.02 [0.01	sk Ratio ixed, 95%CI (3, 3.916) 9, 58.237] 22, 7.857] (6, 1.761]	Favors Su	tureless Fa	wors Suture sk Ratio		
Total events Heterogeneity: Chi ² = 3 Positive surgical Study or Subgroup Feng Zhang 2021 Ching-Chia Li 2020 Dachun Jin 2020 William.J 2005 Jianfei Ye 2018	5.4, df = Z= 0.38 tandard margi Cas 110 33 65 75	\mathbf{n}	$\begin{array}{c} 0.494 \\ 1060 \\ 0.61 \\ 0$	50 $^{2} = 0\%$ suture $e Even 5 3 0 3 2 5 0 $	ts We 35.5 7.4 21.4 35.5	ight 7% 7% 10% 57% aded	RR 0.667 2.941 0.411 0.167	Ris M-H, Fj [0.11 [0.22 [0.01 ex	sk Ratio ixed, 95%CI (3, 3.916) 9, 58.237] 22, 7.857] (6, 1.761]	Favors Su	tureless Fa	wors Suture		
Total events Total events Test for overall effect: R = risk ritio, SD = s Positive surgical Study or Subgroup Feng Zhang 2021 Ching-Chia Li 2020 Dachun Jin 2020 William.J 2005 Jianfei Ye 2018	5.4, df = Z= 0.38 tandard margi Cas Cas 110 5 65 75 78	= 6, (P = 0.7) $= 0.7$ $= 0.7$ $= 0.7$ $= 0.7$ $= 0.7$ $= 0.7$ $= 0.7$ $= 0.7$ $= 0.7$ $= 0.7$ $= 0.7$ $= 0.7$ $= 0.7$ $= 0.7$ $= 0.7$ $= 0.7$	$\begin{array}{c} 0.494 \\ 0.69 \\ 0.60 \\ 0.61 \\ 0.61 \\ 0.62 \\ 0$	50 $2 = 0%$ onfidence suture $e Even$ $5 3$ $0 3$ 2 $5 0$	ts We 35.5 7.4 21.4 35.5 excl	ight 7% 7% 10% 57% aded	RR 0.667 2.941 0.411 0.167 excluded	Ris M-H, Fj [0.11 [0.22 [0.01 ex	sk Ratio ixed, 95%CI 3, 3.916] 9, 58.237] 22, 7.857] 6, 1.761] cluded	Favors Su	tureless Fa	wors Suture		
Total events Heterogeneity: Chi ² = 3 Positive surgical Study or Subgroup Feng Zhang 2021 Ching-Chia Li 2020 Dachun Jin 2020 William.J 2005 Jianfei Ye 2018	5.4, df = Z= 0.38 tandard margi Cas Cas 110 5 65 75 78	\mathbf{n}	$\begin{array}{c} 0.494 \\ 0.69 \\ 0.60 \\ 0.61 \\ 0.61 \\ 0.62 \\ 0$	50 $^{2} = 0\%$ suture $e Even 5 3 0 3 2 5 0 $	ts We 35.5 7.4 21.4 35.5 excl	ight 7% 7% 10% 57% aded	RR 0.667 2.941 0.411 0.167 excluded	Ris M-H, Fj [0.11 [0.22 [0.01 ex	sk Ratio ixed, 95%CI 3, 3.916] 9, 58.237] 22, 7.857] 6, 1.761] cluded	Favors Su	tureless Fa	wors Suture		
Total events Jeterogeneity: Chi ² = 1 2 est for overall effect: 2 R = risk ritio, SD = s Positive surgical Study or Subgroup Feng Zhang 2021 Ching-Chia Li 2020 Dachun Jin 2020 William J 2005 Jianfei Ye 2018 Total Total Total Events	5.4, df ⁻ Z= 0.38 tandard margi st Cas 110 33 65 75 78 285	P = 6, (P = 0.7) $P = 0.7$ $P = 0$	$\begin{array}{c} 0.494) I \\ 066) \\ CI = cc \\ \hline cs \\ Cas \\ 11c \\ 19 \\ 185 \\ 255 \\ 12c \\ 345 \end{array}$	$50^{2} = 0\%$ onfidence suture e Even 5^{3} 0 3^{2} 2 5^{5} 0 8^{3}	ts We 35.5 7.4 21.4 35.5 excl	ight 7% 7% 10% 57% aded	RR 0.667 2.941 0.411 0.167 excluded	Ris M-H, Fj [0.11 [0.22 [0.01 ex	sk Ratio ixed, 95%CI 3, 3.916] 9, 58.237] 22, 7.857] 6, 1.761] cluded	Favors Su	tureless Fa	wors Suture		
Total events Teterogeneity: Chi ² = 3 Set for overall effect: R = risk ritio, SD = s Positive surgical Study or Subgroup Feng Zhang 2021 Ching-Chia Li 2020 Dachun Jin 2020 William.J 2005 Jianfei Ye 2018	5.4, df = Z= 0.38 tandard margi st Cas 110 33 65 75 78 289 2.3, df =		$\begin{array}{c} 0.494) I \\ \hline 006) \\ CI = cc \\ \hline 110 \\ 185 \\ 255 \\ 120 \\ 349 \\ 0.512); \end{array}$	$50^{2} = 0\%$ onfidence suture e Even 5^{3} 0 3^{2} 2 5^{5} 0 8^{3}	ts We 35.5 7.4 21.4 35.5 excl	ight 7% 7% 10% 57% aded	RR 0.667 2.941 0.411 0.167 excluded	Ris M-H, Fj [0.11 [0.22 [0.01 ex	sk Ratio ixed, 95%CI 3, 3.916] 9, 58.237] 22, 7.857] 6, 1.761] cluded	Favors Su	tureless Fa	wors Suture		

FIGURE 4 | Forest plots of postoperative complications and positive surgical margin for sutureless versus suture partial nephrectomy.

biomaterials and electrocoagulation hemostasis in sutureless PN seems to have similar operative outcomes as suture PN. However, there was no difference in surgical blood loss between the two techniques in uncomplex subgroup, which reflected that reduction in clamping rate might lead to more blood loss. Due to the bias of retrospective study and the technical differences between each center that might directly affect the operative blood loss, operation time, and ischemia time, it cannot fully prove that sutureless PN has more advantages. In addition, with the continuous optimization and maturity of suture PN, the difference in operative blood loss and ischemia time might be reduced (25).

Segmental renal artery ligation caused by the suture might lead to the loss of functional renal parenchyma (26-28).

Sutureless PN seems to reduce the potential impact on postoperative renal function, but no difference in postoperative eGFR was found in our study. In the study of Zhang et al. and Jin et al., it was shown that the decline in renal function after sutureless PN was lower than that after suture PN (10, 11). Due to the different diagnostic criteria in the included studies, we could not evaluate the difference in renal function decline to prove that sutureless technique is better than suture technique in renal function protection. In this study, the low positive surgical margin and tumor recurrence reported in the included studies might benefit from the resection near the pseudocapsule of renal tumor, which had been proven to be safe for oncology outcomes (29, 30). Due to the incomplete follow-up data in the included

	Suturele	SS		Suture				Mean Differences	Mean Differences	
Study or Subgroup C	ase Mean	SD	Case	Mean	SD	Weight,	WMD	IV, Fixed, 95%CI	IV, Fixed, 95% CI	
Ching-Chia Li 2020	19 78.3	11.3	21	79.4	13.3	2.86%	-2.6	[-15.438, 10.238]	I	
Daniele Tiscione 2019	69.6	24.3	19	72.2	21.8	5.47%	-1.1	[-8.727, 6.527]		
Total	52		40			100%	-1.491	[-8.049, 5.066]		
$eterogeneity: Chi^2 = 0.04, d$	f = 1 (P =	0 844)	$I^2 = 0\%$							
test for overall effect: $Z=0.4$			1 - 070	,						
GFR= estimated glomerular	filtratin ra	, WMD=	-weight	ed mea	n differe	ence, $SD = s$	standard d	eviation; -20	10 1 -10	20
I = confidence interval.									Favors Sutureless Favors Suture	
umor recurrence										
umor recurrence	su	tureless		sutu	ure			Risk Ratio	Risk Ratio	
Study or Subgroup		tureless Ever			ure Events	Weigh	ıt R			
		Ever	nts C			Weigh 62.50%		R M-H, Fixed, 95%	%CI M-H, Fixed, 95%CI	
Study or Subgroup	Case	Ever	nts C	ase	Events	U	6 0.	R M-H, Fixed, 95% 5 [0.046, 5.438]	M-H, Fixed, 95%CI	
Study or Subgroup Feng Zhang 2021	Case 116	Ever 1	nts C 1	lase 16	Events 2	62.50%	6 0. 6 0.6	R M-H, Fixed, 95% 5 [0.046, 5.438]	M-H, Fixed, 95%CI	
Study or Subgroup Feng Zhang 2021 Dachun Jin 2020	Case 116 65 33	Even 1 0	nts C 1 1	Case 16 89	Events 2 2	62.50% 37.50%	% 0. % 0.6 d	R M-H, Fixed, 95% 5 [0.046, 5.438]	M-H, Fixed, 95%CI	
Study or Subgroup Feng Zhang 2021 Dachun Jin 2020 Ching-Chia Li 2020	Case 116 65 33	Ever 1 0 0	nts C	Case 16 89 19	Events 2 2 0	62.50% 37.50% exclue	% 0. % 0.6 d d	R M-H, Fixed, 95% 5 [0.046, 5.438]	M-H, Fixed, 95%CI	_
Study or Subgroup Feng Zhang 2021 Dachun Jin 2020 Ching-Chia Li 2020 Daniele Tiscione 2019	Case 116 65 33 9 19	Even 1 0 0 0	nts C	Case 16 89 19 21	Events 2 2 0 0	62.50% 37.50% exclue exclue	% 0. % 0.6 d d d	R M-H, Fixed, 95% 5 [0.046, 5.438]	M-H, Fixed, 95%CI	_
Study or Subgroup Feng Zhang 2021 Dachun Jin 2020 Ching-Chia Li 2020 Daniele Tiscione 2019 Jianfei Ye 2018 William.J 2005	Case 116 65 33 9 19 78 75	Ever 1 0 0 0 0 0	nts C	Case 16 89 19 21 26 25	Events 2 2 0 0 0 0	62.50% 37.50% exclue exclue exclue exclue	% 0. % 0.6 d d d d	R M-H, Fixed, 95% 5 [0.046, 5.438] 33 [0.031, 13.010]	6CI M-H, Fixed, 95%CI	_
Study or Subgroup Feng Zhang 2021 Dachun Jin 2020 Ching-Chia Li 2020 Daniele Tiscione 2019 Jianfei Ye 2018 William.J 2005 Total	Case 116 65 33 9 19 78	Ever 1 0 0 0 0 0 0 0	nts C	Case 16 89 19 21 26	Events 2 2 0 0 0 0 0	62.50% 37.50% exclue exclue exclue	% 0. % 0.6 d d d d	R M-H, Fixed, 95% 5 [0.046, 5.438] 33 [0.031, 13.010]	6CI M-H, Fixed, 95%CI	_
Study or Subgroup Feng Zhang 2021 Dachun Jin 2020 Ching-Chia Li 2020 Daniele Tiscione 2019 Jianfei Ye 2018 William.J 2005	Case 116 65 33 9 19 78 75	Ever 1 0 0 0 0 0	nts C	Case 16 89 19 21 26 25	Events 2 2 0 0 0 0	62.50% 37.50% exclue exclue exclue exclue	% 0. % 0.6 d d d d	R M-H, Fixed, 95% 5 [0.046, 5.438] 33 [0.031, 13.010]	6CI M-H, Fixed, 95%CI	_
Study or Subgroup Feng Zhang 2021 Dachun Jin 2020 Ching-Chia Li 2020 Daniele Tiscione 2019 Jianfei Ye 2018 William J 2005 Total Total Total Events	Cass 116 65 33 9 19 78 75 181	: Ever 1 0 0 0 0 0 1	nts C 1 1 1 1 2 3	Case 116 189 19 21 226 225 805	Events 2 2 0 0 0 0 0 4	62.50% 37.50% exclue exclue exclue exclue	% 0. % 0.6 d d d d	R M-H, Fixed, 95% 5 [0.046, 5.438] 33 [0.031, 13.010]	6CI M-H, Fixed, 95%CI	_
Study or Subgroup Feng Zhang 2021 Dachun Jin 2020 Ching-Chia Li 2020 Daniele Tiscione 2019 Jianfei Ye 2018 William.J 2005 Total	Case 116 65 33 9 78 75 181 1, df = 1,	$\frac{\text{Ever}}{1} \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 1 \\ (P = 0.9)$	nts <u>C</u> 1 1 1 1 1 2 3 3	Case 116 189 19 21 226 225 805	Events 2 2 0 0 0 0 0 4	62.50% 37.50% exclue exclue exclue exclue	% 0. % 0.6 d d d d	R M-H, Fixed, 95% 5 [0.046, 5.438] 33 [0.031, 13.010]	6CI M-H, Fixed, 95%CI	-

FIGURE 5 | Forest plots of postoperative eGFR and tumor recurrence for sutureless versus suture partial nephrectomy.

studies, more detailed data are needed to assess the long-term prognosis of sutureless and suture PN.

In this study, outcomes of sutureless and suture PN in perioperative were similar, and sutureless PN might have potential advantages in protecting renal function. However, in larger and more complex T1b RCC, which requires more extensive parenchyma resection and reconstruction, the potential risk may be greater. Overall, under strict preoperative and intraoperative evaluation, sutureless PN could be a feasible choice for smaller T1a RCC, whereas should not be overestimated in T1b RCC.

Our research has some limitations. First, the meta-analysis of retrospective studies, which have an inherent bias, could not fully compare the pros and cons between the two techniques. Second, the technical differences and diagnostic criteria between different time periods and different centers and heterogeneity between

Outcomes	Begg's test	Eg	ger' s test
		P value	95% CI
Operative time	Pr > z = 0.548	P > t = 0.317	[7072611, 1.784052]
Warm ischemia time	Pr > z = 0.174	P > t = 0.047	[0.1128378, 11.70039]
Clamping rate	Pr > z = 1.000	P > t = 0.774	[-2.500231, 2.650236]
Estimated blood loss	Pr > z = 1.000	P > t = 0.558	[-3.782394, 2.252696]
Postoperative complications	Pr > z = 0.368	P > t = 0.757	[-1.836992, 2.371768]
Positive surgical margin	Pr > z = 0.734	P > t = 0.554	[-7.953917, 11.07025]
postoperative eGFR	Pr > z = 1	NA	NA
Tumor recurrence	Pr > z = 1	NA	NA

eGFR, estimated glomerular filtration rat; CI, confidence interval, NA, not applicable.

studies were inevitable. Analysis of the sources of heterogeneity requires more detailed subgroup data. Third, due to the lack of oncology outcome-related data, we cannot better evaluate the surgical prognosis. Lastly, only eight retrospective studies are included in this analysis, and more high-quality studies are needed in the future.

CONCLUSION

Our meta-analysis suggested that the two surgical techniques have similar perioperative outcomes in T1a RCC with low RENAL score. In addition, sutureless PN might have potential advantages in the protection of renal function. In some cases, sutureless PN is a feasible choice under strict preoperative and intraoperative evaluation. However, application in larger and more complex T1b needs to be cautiously made. More welldesigned prospective randomized clinical trials are needed for further research in the future.

REFERENCES

- Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Fernández-Pello S, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. *Eur Urol* (2019) 75:799–810. doi: 10.1016/ j.eururo.2019.02.011
- Campbell S, Uzzo RG, Allaf ME, Bass EB, Cadeddu JA, Chang A, et al. Renal Mass and Localized Renal Cancer: AUA Guideline. J Urol (2017) 198:520–9. doi: 10.1016/j.juro.2017.04.100
- Huang WC, Levey AS, Serio AM, Snyder M, Vickers AJ, Raj GV, et al. Chronic Kidney Disease After Nephrectomy in Patients With Renal Cortical Tumours: A Retrospective Cohort Study. *Lancet Oncol* (2006) 7:735–40. doi: 10.1016/S1470-2045(06)70803-8
- Zabell JR, Wu J, Suk-Ouichai C, Campbell SC. Renal Ischemia and Functional Outcomes Following Partial Nephrectomy. Urol Clin North Am (2017) 44:243–55. doi: 10.1016/j.ucl.2016.12.010
- Patel HD, Pierorazio PM, Johnson MH, Sharma R, Iyoha E, Allaf ME, et al. Renal Functional Outcomes After Surgery, Ablation, and Active Surveillance of Localized Renal Tumors: A Systematic Review and Meta-Analysis. *Clin J Am Soc Nephrol* (2017) 12:1057–69. doi: 10.2215/CJN.11941116
- Mir MC, Derweesh I, Porpiglia F, Zargar H, Mottrie A. Autorino R. Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-Analysis of Comparative Studies. *Eur Urol* (2017) 71:606–17. doi: 10.1016/j.eururo.2016.08.060
- Volpe A, Blute ML, Ficarra V, Gill IS, Kutikov A, Porpiglia F, et al. Renal Ischemia and Function After Partial Nephrectomy: A Collaborative Review of the Literature. *Eur Urol* (2015) 68:61–74. doi: 10.1016/j.eururo.2015.01.025
- Simone G, Papalia R, Guaglianone S, Gallucci M. 'Zero Ischaemia', Sutureless Laparoscopic Partial Nephrectomy for Renal Tumours With a Low Nephrometry Score. BJU Int (2012) 110:124–30. doi: 10.1111/j.1464-410X.2011.10782.x
- Dell'Atti L, Scarcella S, Manno S, Polito M, Galosi AB. Approach for Renal Tumors With Low Nephrometry Score Through Unclamped Sutureless Laparoscopic Enucleation Technique: Functional and Oncologic Outcomes. *Clin Genitourin Cancer* (2018) 16:e1251–6. doi: 10.1016/j.clgc.2018.07.020
- Jin D, Ren D, Zhang J, Xu G, Ge C, Jiang Q, et al. A Propensity Score-Matched Comparison Between Sutureless and Suture Techniques in Laparoscopic Nephron-Sparing Surgery: A Retrospective Non-Randomized Observational Study. *J Laparoendosc Adv Surg Tech A* (2020) 30:1314–9. doi: 10.1089/lap.2020.0187
- Zhang F, Gao S, Zhao Y, Wu B, Chen X. Comparison of Sutureless and Conventional Laparoscopic Partial Nephrectomy: A Propensity Score-Matching Analysis. Front Oncol (2021) 11:649356. doi: 10.3389/fonc.2021.649356

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS

Study concept and design: KT and WZ. Data acquisition: WZ, BC, SX, YM, and JH. Data analysis: WZ, BC, and SX. Drafting of manuscript: WZ. Critical revision of the manuscript: KT. All authors contributed to the article and approved the submitted version.

FUNDING

This study was supported by the Science and Technology Fund Project of Guizhou Health Commission (gzwkj2021-211).

- Johnston WR, Montgomery JS, Seifman BD, Hollenbeck BK, Wolf JJ. Fibrin Glue V Sutured Bolster: Lessons Learned During 100 Laparoscopic Partial Nephrectomies. J Urol (2005) 174:47-52. doi: 10.1097/ 01.ju.0000162041.64143.08
- Ye J, Zhang S, Tian X, Wang G, Zhao L, Ma L. Knotless Retroperitoneoscopic Nephron-Sparing Surgery for Small Renal Masses: Comparison of Bipolar Sutureless Technique and Barbed Suture Technique. J Int Med Res (2018) 46:1649–56. doi: 10.1177/0300060518760737
- Li CC, Chien TM, Huang SP, Yeh HC, Lee HY, Ke HL, et al. Single-Site Sutureless Partial Nephrectomy for Small Exophytic Renal Tumors. J Clin Med (2020) 9:3658. doi: 10.3390/jcm9113658
- Minervini A, Siena G, Tuccio A, Lapini A, Serni S, Carini M. Sutureless Hemostatic Control During Laparoscopic NSS for the Treatment of Small Renal Masses. Surg Innov (2014) 21:32–8. doi: 10.1177/1553350613484823
- Tiscione D, Cai T, Luciani LG, Puglisi M, Mattevi D, Nesi G, et al. Sutureless Laparoscopic Partial Nephrectomy Using Fibrin Gel Reduces Ischemia Time While Preserving Renal Function. *Arch Ital Urol Androl* (2019) 91:30–4. doi: 10.4081/aiua.2019.1.30
- Hidas G, Kastin A, Mullerad M, Shental J, Moskovitz B, Nativ O. Sutureless Nephron-Sparing Surgery: Use of Albumin Glutaraldehyde Tissue Adhesive (BioGlue). Urology (2006) 67:697–700; discussion 700. doi: 10.1016/ j.urology.2005.10.064
- Wan X, Wang W, Liu J, Tong T. Estimating the Sample Mean and Standard Deviation From the Sample Size, Median, Range and/or Interquartile Range. BMC Med Res Methodol (2014) 14:135. doi: 10.1186/1471-2288-14-135
- Hozo SP, Djulbegovic B, Hozo I. Estimating the Mean and Variance From the Median, Range, and the Size of a Sample. *BMC Med Res Methodol* (2005) 5:13. doi: 10.1186/1471-2288-5-13
- Hung AJ, Cai J, Simmons MN, Gill IS. "Trifecta" in Partial Nephrectomy. J Urol (2013) 189:36–42. doi: 10.1016/j.juro.2012.09.042
- Mir MC, Ercole C, Takagi T, Zhang Z, Velet L, Remer EM, et al. Decline in Renal Function After Partial Nephrectomy: Etiology and Prevention. J Urol (2015) 193:1889–98. doi: 10.1016/j.juro.2015.01.093
- 22. Porpiglia F, Fiori C, Bertolo R, Angusti T, Piccoli GB, Podio V, et al. The Effects of Warm Ischaemia Time on Renal Function After Laparoscopic Partial Nephrectomy in Patients With Normal Contralateral Kidney. World J Urol (2012) 30:257–63. doi: 10.1007/s00345-011-0729-5
- 23. Simone G, Gill IS, Mottrie A, Kutikov A, Patard JJ, Alcaraz A, et al. Indications, Techniques, Outcomes, and Limitations for Minimally Ischemic and Off-Clamp Partial Nephrectomy: A Systematic Review of the Literature. *Eur Urol* (2015) 68:632–40. doi: 10.1016/j.eururo.2015.04.020

- 24. Klatte T, Ficarra V, Gratzke C, Kaouk J, Kutikov A, Macchi V, et al. Gill IS. A Literature Review of Renal Surgical Anatomy and Surgical Strategies for Partial Nephrectomy. *Eur Urol* (2015) 68:980–92. doi: 10.1016/ j.eururo.2015.04.010
- Bertolo R, Campi R, Klatte T, Kriegmair MC, Mir MC, Ouzaid I, et al. Suture Techniques During Laparoscopic and Robot-Assisted Partial Nephrectomy: A Systematic Review and Quantitative Synthesis of Peri-Operative Outcomes. *Bju Int* (2019) 123:923–46. doi: 10.1111/bju.14537
- Bahler CD, Sundaram CP. Effect of Renal Reconstruction on Renal Function After Partial Nephrectomy. J Endourol (2016) 30(Suppl 1):S37–41. doi: 10.1089/end.2016.0055
- Dong W, Wu J, Suk-Ouichai C, Caraballo AE, Remer E, Li J, et al. Devascularized Parenchymal Mass Associated With Partial Nephrectomy: Predictive Factors and Impact on Functional Recovery. *J Urol* (2017) 198:787– 94. doi: 10.1016/j.juro.2017.04.020
- Porpiglia F, Bertolo R, Amparore D, Fiori C. Nephron-Sparing Suture of Renal Parenchyma After Partial Nephrectomy: Which Technique to Go For? Some Best Practices. *Eur Urol Focus* (2019) 5:600–3. doi: 10.1016/j.euf.2017.08.006
- Azhar RA, de Castro AA, Broxham E, Sherrod A, Ma Y, Cai J, et al. Histological Analysis of the Kidney Tumor-Parenchyma Interface. J Urol (2015) 193:415–22. doi: 10.1016/j.juro.2014.08.010

 Minervini A, di Cristofano C, Lapini A, Marchi M, Lanzi F, Giubilei G, et al. Histopathologic Analysis of Peritumoral Pseudocapsule and Surgical Margin Status After Tumor Enucleation for Renal Cell Carcinoma. *Eur Urol* (2009) 55:1410–8. doi: 10.1016/j.eururo.2008.07.038

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Zhang, Che, Xu, Mu, He and Tang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.